HT-2157
![]() | |
![]() | |
Clinical data | |
---|---|
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
ChemSpider | |
UNII | |
Chemical and physical data | |
Formula | C21H13F3N2O |
Molar mass | 366.343 g·mol−1 |
3D model (JSmol) | |
| |
|
HT-2157 (former development code SNAP-37889) is a drug which acts as a selective non-peptide antagonist for the receptor GAL-3, which is usually activated by the neuropeptide galanin. Blocking this receptor with HT-2157 produced increased serotonin release,[1] as well as producing antidepressant and anxiolytic effects in animal studies,[2] and it was also being researched for treatment of cognitive dysfunction.[3] All human clinical trials were terminated due to safety concerns however, and new GAL-3 antagonists are now being sought instead.[4]
References
[edit]- ^ "pA2 Online". www.pa2online.org.
- ^ Swanson CJ, Blackburn TP, Zhang X, Zheng K, Xu ZQ, Hökfelt T, et al. (November 2005). "Anxiolytic- and antidepressant-like profiles of the galanin-3 receptor (Gal3) antagonists SNAP 37889 and SNAP 398299". Proceedings of the National Academy of Sciences of the United States of America. 102 (48): 17489–94. doi:10.1073/pnas.0508970102. PMC 1283534. PMID 16287967.
- ^ US 8277842, Kaplan AP, "Enteric-coated HT-2157 compositions and methods of their use", published January 20, 2012
- ^ "Dart NeuroScience LLC -- Scientific Advisory Board". www.dartneuroscience.com.